Circulating cell-free tumor DNA（ctDNA） in the blood is DNA released from apoptotic, circulating, and living tumor cells. ctDNA is about 140 nt in length and has a half-life of about 1.5 h. ctDNA analysis provides a ...Circulating cell-free tumor DNA（ctDNA） in the blood is DNA released from apoptotic, circulating, and living tumor cells. ctDNA is about 140 nt in length and has a half-life of about 1.5 h. ctDNA analysis provides a noninvasive means to assess the genetic profile of cancer in real time. With the advent of molecular technologies, including digital PCR and massively parallel sequencing（MPS）, ctDNA analysis has shown promise as a highly sensitive and specific alternative to conventional tissue biopsy in cancer detection, longitudinal monitoring, and precision therapy. This review provides an overview of the latest development in our understanding of the biologic characteristics, detection methodologies, and potential clinical implications of ctDNA, as well as the challenges in translating ctDNA analysis from the research arena to patient care.展开更多
The physical datum method that uses the laser beam as the physical datum is proposed.A high accuracy of the straight movement on the line above 0.01 μm/100 mm is achieved through applying the method of the closed lo...The physical datum method that uses the laser beam as the physical datum is proposed.A high accuracy of the straight movement on the line above 0.01 μm/100 mm is achieved through applying the method of the closed loop feedback control that uses the laser beam as the datum.The measuring accuracy above 0.05 μm is obtained by applying the self making electric eddy displacement sensor to detect the geometric accuracy of the optical flat.It proves that the laser beam datum method can achieve the high accurcy of the straight movement and has the huge advantage.展开更多
In the era of precision oncology,molecular profiling of tumor biopsy or plasma(also known as liquid biopsy)derived from patients with cancer is pivotal in guiding treatment selection.Liquid biopsy allows for the ident...In the era of precision oncology,molecular profiling of tumor biopsy or plasma(also known as liquid biopsy)derived from patients with cancer is pivotal in guiding treatment selection.Liquid biopsy allows for the identification of druggable biomarkers,facilitating optimal cancer care management.1 Non-small cell lung cancer(NSCLC)is at the forefront because of the diverse genetic biomarkers currently approved for guiding targeted therapies.Mesenchymal epithelial transition(MET)is a receptor tyrosine kinase with pleiotropic functions,such as initiating and sustaining neoplastic transformation,driving cancer clonal evolution,and progression toward metastasis after treatment initiation and under therapeutic pressure.2 Exon 14 skipping(METex14skipping)and amplification(METamp)are two important MET dysregulations in NSCLC with distinct oncogenic roles.The concurrent presence of these two MET alterations in patients with NSCLC has rarely been reported,and knowledge of their collective impact on patient response to MET inhibitors such as capmatinib remains elusive.In this paper,we report the case of a 60-year-old woman diagnosed with lung adenocarcinoma and brain metastasis who progressed on first-line(1L)osimertinib treatment with new liver metastasis,along with the outcomes of subsequent testing and treatment management.展开更多
文摘Circulating cell-free tumor DNA（ctDNA） in the blood is DNA released from apoptotic, circulating, and living tumor cells. ctDNA is about 140 nt in length and has a half-life of about 1.5 h. ctDNA analysis provides a noninvasive means to assess the genetic profile of cancer in real time. With the advent of molecular technologies, including digital PCR and massively parallel sequencing（MPS）, ctDNA analysis has shown promise as a highly sensitive and specific alternative to conventional tissue biopsy in cancer detection, longitudinal monitoring, and precision therapy. This review provides an overview of the latest development in our understanding of the biologic characteristics, detection methodologies, and potential clinical implications of ctDNA, as well as the challenges in translating ctDNA analysis from the research arena to patient care.
文摘The physical datum method that uses the laser beam as the physical datum is proposed.A high accuracy of the straight movement on the line above 0.01 μm/100 mm is achieved through applying the method of the closed loop feedback control that uses the laser beam as the datum.The measuring accuracy above 0.05 μm is obtained by applying the self making electric eddy displacement sensor to detect the geometric accuracy of the optical flat.It proves that the laser beam datum method can achieve the high accurcy of the straight movement and has the huge advantage.
文摘In the era of precision oncology,molecular profiling of tumor biopsy or plasma(also known as liquid biopsy)derived from patients with cancer is pivotal in guiding treatment selection.Liquid biopsy allows for the identification of druggable biomarkers,facilitating optimal cancer care management.1 Non-small cell lung cancer(NSCLC)is at the forefront because of the diverse genetic biomarkers currently approved for guiding targeted therapies.Mesenchymal epithelial transition(MET)is a receptor tyrosine kinase with pleiotropic functions,such as initiating and sustaining neoplastic transformation,driving cancer clonal evolution,and progression toward metastasis after treatment initiation and under therapeutic pressure.2 Exon 14 skipping(METex14skipping)and amplification(METamp)are two important MET dysregulations in NSCLC with distinct oncogenic roles.The concurrent presence of these two MET alterations in patients with NSCLC has rarely been reported,and knowledge of their collective impact on patient response to MET inhibitors such as capmatinib remains elusive.In this paper,we report the case of a 60-year-old woman diagnosed with lung adenocarcinoma and brain metastasis who progressed on first-line(1L)osimertinib treatment with new liver metastasis,along with the outcomes of subsequent testing and treatment management.
